CRIS Current Research Information System

VERUCCHI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.393
EU - Europa 5.104
AS - Asia 2.313
AF - Africa 282
SA - Sud America 13
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.117
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.382
GB - Regno Unito 1.900
CN - Cina 921
SE - Svezia 698
SG - Singapore 634
DE - Germania 627
IT - Italia 601
VN - Vietnam 344
UA - Ucraina 307
IN - India 303
IE - Irlanda 218
RU - Federazione Russa 218
FR - Francia 194
EE - Estonia 106
ZA - Sudafrica 105
TG - Togo 85
BG - Bulgaria 58
CI - Costa d'Avorio 45
FI - Finlandia 45
JO - Giordania 44
CH - Svizzera 36
NG - Nigeria 23
SC - Seychelles 19
ES - Italia 18
BE - Belgio 17
GR - Grecia 15
NL - Olanda 14
ID - Indonesia 12
CA - Canada 10
IR - Iran 10
LB - Libano 9
AU - Australia 7
JP - Giappone 7
LU - Lussemburgo 6
BR - Brasile 5
CL - Cile 5
UZ - Uzbekistan 5
AT - Austria 4
IL - Israele 4
RO - Romania 4
TR - Turchia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
EG - Egitto 3
HK - Hong Kong 3
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
HR - Croazia 2
MM - Myanmar 2
NZ - Nuova Zelanda 2
PL - Polonia 2
PT - Portogallo 2
RS - Serbia 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
EC - Ecuador 1
LT - Lituania 1
MA - Marocco 1
ME - Montenegro 1
MK - Macedonia 1
MN - Mongolia 1
MX - Messico 1
NO - Norvegia 1
PE - Perù 1
PK - Pakistan 1
SI - Slovenia 1
SN - Senegal 1
TH - Thailandia 1
TJ - Tagikistan 1
Totale 15.117
Salva come PNG Salva come JPEG
Città #
Southend 1.779
Fairfield 975
Chandler 665
Singapore 564
Ashburn 553
Houston 482
Woodbridge 473
Seattle 435
Wilmington 426
Santa Clara 330
Cambridge 310
Princeton 310
Ann Arbor 264
Dublin 217
Dong Ket 213
Jacksonville 195
Boardman 189
Bologna 134
Westminster 130
Nanjing 125
Padova 118
Berlin 89
Lomé 85
San Diego 80
Shenyang 69
Saint Petersburg 63
Jinan 58
Sofia 57
New York 55
Beijing 52
Redmond 48
Abidjan 45
Amman 44
Florence 43
Helsinki 43
Nanchang 42
Dearborn 40
Changsha 38
Hebei 36
Guangzhou 34
Des Moines 33
Mülheim 31
Zhengzhou 30
Medford 28
Milan 28
Tianjin 28
Turin 27
Falls Church 26
Norwalk 23
Abeokuta 22
Bremen 22
Bern 21
Redwood City 21
Jiaxing 19
Mahé 19
Olalla 19
Bühl 17
Hangzhou 17
Ningbo 17
Shanghai 16
Brussels 15
London 15
Verona 15
Benevento 14
Haikou 14
Fuzhou 13
Hefei 13
Lanzhou 13
Los Angeles 13
Phoenix 13
Wuhan 13
Taiyuan 12
Jakarta 11
Mountain View 11
Leganés 10
Moscow 10
Rome 10
Kunming 9
Pune 9
Chengdu 8
Frankfurt Am Main 8
Frankfurt am Main 8
Toronto 8
Nuremberg 7
San Venanzo 7
Shijiazhuang 7
Chicago 6
Falkenstein 6
Luxembourg 6
Paris 6
Reggio Emilia 6
San Jose 6
Atlanta 5
Chongqing 5
Genzano Di Roma 5
Imola 5
Lausanne 5
Monmouth Junction 5
Qingdao 5
Shenzhen 5
Totale 10.734
Salva come PNG Salva come JPEG
Nome #
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 422
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 343
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 221
Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: an observational multicenter study 182
A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. 180
Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. 177
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 177
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 174
Chagas Disease in a Non-endemic Country: A Multidisciplinary Research, Bologna, Italy 156
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 155
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 149
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 147
Infectious diseases team for the early management of severe sepsis and septic shock in the emergency department 147
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 146
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 143
Seroprevalence of five neglected parasitic diseases among immigrants accessing five infectious and tropical diseases units in Italy: a cross-sectional study 141
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 140
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 138
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 138
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 134
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study 133
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 133
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 131
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 130
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. 129
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 128
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 127
Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals 127
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients 127
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 126
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 126
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 124
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 123
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 123
105) ANTIVIRAL TREATMENT OF HEPATITIS C IN ITALIAN CHILDREN 122
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 122
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 121
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 120
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 120
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 119
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 118
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 117
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. 117
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. 117
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 116
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 116
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 116
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 115
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 115
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 115
Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. 114
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 114
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 114
Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals 113
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 113
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 113
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 112
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 110
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 109
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 109
Occult HBV infection in PBMCs of HIV+ individuals 107
null 107
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 107
Measles outbreak in the city of Bologna, December 2007 to May 2008 104
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 104
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program 104
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study. 103
Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades 102
Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. 101
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 99
Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical intervention. 99
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 99
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. 99
Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. 99
Patterns and correlations of ALT in a large sample of children with chronic HCV infection 98
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 96
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 96
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 96
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 95
Una rara complicanza infettiva in corso di trapianto ortotopico di fegato: gestione della peritonite tubercolare 93
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 93
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 92
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy. 91
null 90
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 89
Missed treatment in an Italian HBV infected patients cohort: HBV RER 89
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 89
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 89
Nucleoside analogue transcriptase inhibitors and liver toxicity among patients treated for hiv disease 88
Patterns and correlations of ALT in a large sample of children with chronic HCV infection 88
Patterns and correlations of ALT in a large sample of children with chronic HCV infection 88
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 88
Effect of hepatitisC virus genotype on CD4+T cell count in a cohort of Antiretroviral-naive HIV-1-infeted individuals 87
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 87
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. 86
HCV genotypes and pediatric HCV infection 85
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 85
Terapia della infezione da virus C 83
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. 83
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 83
Totale 12.165
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.925
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.174 0 0 0 0 0 0 505 504 500 266 134 265
2020/20212.150 431 161 116 99 64 156 66 131 186 161 129 450
2021/20222.890 250 126 181 250 229 143 91 251 92 280 574 423
2022/20232.696 275 366 149 392 183 209 71 158 478 91 212 112
2023/2024685 60 126 43 54 50 142 40 55 30 34 20 31
2024/20251.752 121 522 239 234 481 152 3 0 0 0 0 0
Totale 15.488